oritavancin Side Effects
Also known as: Orbactiv
Analysis of 896 adverse event reports submitted to the FDA from 2014 to 2025.
Total Reports
896
Death-Related
30
3.3% of reports
Hospitalizations
161
18.0% of reports
Top Indication
Product Used For Unknown Indication
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 30 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| DEATH | 7 |
| OFF LABEL USE | 6 |
| CARDIAC ARREST | 5 |
| BACK PAIN | 4 |
| DYSPNOEA | 4 |
| NAUSEA | 4 |
| BLISTER | 3 |
| CHILLS | 3 |
| DRUG INEFFECTIVE | 3 |
| DRUG RESISTANCE | 3 |
| ACUTE KIDNEY INJURY | 2 |
| CARDIAC FAILURE CONGESTIVE | 2 |
| INFUSION RELATED REACTION | 2 |
| PRURITUS | 2 |
| SEPSIS | 2 |
| URTICARIA | 2 |
| VOMITING | 2 |
| ABDOMINAL PAIN | 1 |
| ACUTE MYELOID LEUKAEMIA | 1 |
| ACUTE MYOCARDIAL INFARCTION | 1 |
Reactions in Hospitalization Reports
Top reactions in 161 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| CHILLS | 31 |
| DYSPNOEA | 29 |
| OFF LABEL USE | 29 |
| NAUSEA | 19 |
| BACK PAIN | 16 |
| CHEST PAIN | 15 |
| DRUG INEFFECTIVE | 15 |
| PYREXIA | 14 |
| VOMITING | 14 |
| INFUSION RELATED REACTION | 13 |
| AGRANULOCYTOSIS | 12 |
| TACHYCARDIA | 12 |
| PRURITUS | 10 |
| URTICARIA | 10 |
| ERYTHEMA | 9 |
| TREMOR | 9 |
| HYPOTENSION | 8 |
| MULTIPLE USE OF SINGLE-USE PRODUCT | 8 |
| RASH | 8 |
| DIZZINESS | 7 |
Nearby — Related Medications
What the FAERS Data Reveals About oritavancin Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 896 voluntary reports linked to oritavancin and its brand equivalents (Orbactiv), spanning 2014 through 2025. Of those, 30 (3.3%) listed death as an outcome and 161 (18.0%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 52% were female and 48% male; age distribution skews toward 45-64, with 180 reports in that bracket. The single most reported reaction is off label use with 173 submissions, followed by pruritus and urticaria.
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice — speak with a licensed clinician about any side-effect concerns.
Read our methodology — how this data is sourced, computed, and verified.